Yui-Wing Francis  Lam, Ph.D.

Significant variability in efficacy and toxicity of medications among patients is largely attributed to innate differences in their capacity to eliminate and react to medications.  Dr. Lam has studied how ethnicity and genetic differences affect disposition and response to psychotherapeutic drugs.  This has translated to improved understanding of the biological basis for why patients require different doses to elicit appropriate responses, particularly Asians.  Dr. Lam’s earlier findings suggested a genetic basis for variation in drug metabolism and response in Mexican Americans in San Antonio.  His current focus is whether variation in genes that encode enzymes, transporters, and targets in Hispanics can be utilized for personalized cancer therapy, and is working with CTRC investigators to integrate pharmacogenomics into anticancer drug development.

• Professional Background

  Education

  • 1984 - PharmD - Clinical Pharmacy - College of Pharmacy, University of Minnesota
  • 1981 - Pharmacy (Graduated with Honors) - School of Pharmacy, University of Bradford
  • Postdoctoral Fellowship - Pharmacokinetics and Pharmacodynamics - School of Pharmacy and Drug Studies Unit, Univ. of California San Francisco
  • Residency - Cardiology and Pharmacokinetics - College of Pharmacy, University of Minnesota

  Appointments

  • 9/2010 - Professor of Pharmacology - The University of Texas Health Science Center at San Antonio, Pharmacology, San Antonio
  • 9/1997 - Associate Professormof Medicine - The University of Texas Health Science Center at San Antonio, Medicine, San Antonio
  • 9/1995 - Clinical Associate Professormof Pharmacy - The University of Texas at Austin, College of PharmacyAustin

• Instruction & Training

  • 7/2019 - Present, PHAR 5023 Drug Discovery and Development, The University of Texas Health Science Center
  • 1/2019 - Present, Advanced Head Neck/Oral, The University of Texas Health Science Center
  • 8/2018 - Present, Renal, Gastrointestinal and Liver, The University of Texas Health Science Center
  • 7/2018 - Present, Cardiovascular and Pulmonary Systems, The University of Texas Health Science Center
  • 4/2018 - Present, Biological Foundations, The University of Texas Health Science Center
  • 3/2018 - Present, Periodontium and Pulp, The University of Texas Health Science Center
  • 9/2017 - Present, Craniofacial Complex, The University of Texas Health Science Center
  • 8/2016 - Present, Pharmacological Principles in Physical Therapy, The University of Texas Health Science Center
  • 6/2016 - Present, PHAR7002, The University of Texas Health Science Center
  • 1/2015 - Present, Pharmacology II, The University of Texas Health Science Center
  • 7/2014 - Present, Pharmacology I, The University of Texas Health Science Center
  • 9/2012 - Present, CIRC 5007 Fundamentals: Molecules to Medicine
  • 9/2010 - Present, PHM 483-Pharmacotherapeutics I, University of Texas at Austin
  • 8/2002 - Present, PGS 381W/PHAR 6020-Molecular and Pharmacological Basis of Therapeutics, UTA and UTHSCSA
  • 8/2000 - Present, Clinical Pharmacology, The University of Texas Health Science Center
  • 8/1993 - Present, Prin of Pharmacology I, The University of Texas Health Science Center

• Research & Grants

  Significant variability in efficacy and toxicity of medications among patients is largely attributed to innate differences in their capacity to eliminate and react to medications.  Dr. Lam has studied how ethnicity and genetic differences affect disposition and response to psychotherapeutic drugs.  This has translated to improved understanding of the biological basis for why patients require different doses to elicit appropriate responses, particularly Asians.  Dr. Lam’s earlier findings suggested a genetic basis for variation in drug metabolism and response in Mexican Americans in San Antonio.  

  Grants

  Private

  Funding Agency Voelcker Foundation Title The Max and Minnie Tomerlin Voelcker Biomedical Research Academy Status Active Period 6/2018 - 5/2022 Role Co-Principal Investigator Grant Detail  

• Publications

  • Metformin modifies disparity in hepatocellular coarcinoma incidence in men with type 2 diabetes but without chronic liver diseas

  Abstract

  Chapa I, J Hensler F Lam, L McManus, A Giuffrida, E Russell-McKenzie, AL DePass. Examining outcomes of the Voelcker Biomedical Research Academy (VBRA) for high school students; 2017 Mar. (Proceedings of Understanding Interventions That Broaden Participation in Science Careers). Wang Chen-Pin, Kuhn John, Lam Yui-Wing F, DeFronzo Ralph A, Alkhouri Naim. The Use of Metformin Reduces the Burden Of Chronic Liver Diseases in Hispanic Veterans with Type 2 Diabetes; 2017 Jan. (Hepatology; vol. 66, no. 1). Macy B, Lam YWF, Lam A. Comparing the Pharmacokinetics of Rectally Administered Phenobarbital Tablets in Microenema Form versus Suppository; 2016 Jan. (Journal of Pain and Symptom Management; vol. 51, no. 2). Wang C, Lehman D, Lam Y, Kuhn J, Mahalingam D, Weitman S, Hernandez J, Lorenzo C, Downs J, Espinoza S, Ramirez A. Metformin reduces prostate cancer disparity in men with type 2 diabetes?; 2015 Jun. (Diabetes; vol. 64, no. S1).

  Book Chapter

  Lam YF. Role of Pharmacogenomics in Diabetes. In: Lam YWF, Duggirala, R, Jenkinson C, Arya, R. Pharmacogenomics: Challenges and Opportunities in Therapeutic Implementation. Lam YWF, Scott S (ed). 2nd edition. p. 247-269. Lam YF. Economic Evaluation of Phamacogenomic Testing: Lessons from Psychiatric Pharmacogenomics. In: Lam YWF. Pharmacogenomics: Challenges and Opportunities in Therapeutic Implementation. Lam YWF, Scott S (ed). 2nd edition. 2019. p. 385-394. Lam YF. Pharmacogenomics in Psychiatric Disorders. In: Lam YWF, Someya T. Pharmacogenomics: Challenges and Opportunities in Therapeutic Implementation. Lam YWF, Scott S (ed). 2nd edition. 2019. p. 247-269. Lam YF. Pharmacokinetic, Pharmacodynamic, and Clinical Implications. In: Pharmacogenomics. In: Lam YWF. Challenges and Opportunities in Therapeutic Implementation. Lam YWF, Scott S (ed). 2nd edition. 2019. p. 1-53. Lam YWF. Translating Pharmacogenomic Research to Therapeutic Potentials. In: Lam YWF. Challenges and Opportunities in Therapeutic Implementation. Lam YWF, Scott S (ed). 2nd edition. 2019. p. 181-225. Lam Y. Pharmacogenomics in Cancer Therapeutics. In: Lam YWF, Scott, SA. Challenges and Opportunities in Therapeutic Implementation. Lam YWF, Scott S (ed). 2nd edition. 2019. p. 123-132. Cavallari L, Lam YWF. Pharmacogenetics. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (Editors). Pharmacotherapy: A Pathophysiologic Approach, 10th edition. New York, New York: McGraw-Hill; 2017. Lam YWF. Clinically Significant Drug Interactions With Psychopharmacological Agents: Antidepressants. In: Jann, MW, Penzak S, Cohen L (ed). Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents. 2016. p. 451-469.

  Book/Monograph

  Lam YWF, Scott S (editors). Pharmacogenomics: Challenges and Opportunities in Therapeutic Implementation. 2nd edition 2019.

  Journal Article

  Wang CP, Kuhn J, Shah DP, Schmidt S, Lam YF, MacCarthy D, Tenner L, Ramirez AG. Metformin modifies disparity in hepatocellular carcinoma incidence in men with type 2 diabetes but without chronic liver diseases Cancer Medicine 2019 Apr;8(6):3206-3215. Hermann R, Lam YWF, Spackman G. True Allergic Reaction to Amide Local Anesthetics such as Lidocaine is Confirmed by Immunologic Testing Texas Dental Journal 2016 Feb;133. Lam YF, Lam A, Macy B. Pharmacokinetics of Phenobarbital in Micro-enema Via Macy Catheter versus Suppository Journal of Pain and Symptom Management 2016 Jan;51:994-1001. Wang CP, Lehman D, Lam YWF, Kuhn J, Mahalingam D, Weitman S, Lorenzo C, Downs JD, Stuart EA, Hernandez J, Thompson IM, Ramirez AG
  . Metformin for Reducing Racial/Ethnic Difference in Prostate Cancer Incidence for Men with Type 2 Diabetes Cancer Prevention Research 2016 Jan;9:779-787.

  Not Specified

  Lam YF. Principles of Pharmacogenomics: Pharmacokinetic, Pharmacodynamic, and Clinical Implications. In: Pharmacogenomics 2019 Jan;:1-53.